Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Abiomed's Return On Capital Employed Insights

According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Abiomed is not utilizing their capital as effectively as possible. Abiomed reached earnings of $56.95 million and sales of $248.14 million in Q2.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.